Trial Profile
Phase I Clinical Trial on Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms GlitIpNi
- 08 Nov 2023 Results published in the Clinical Cancer Research
- 10 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2022 Results (N=14) presented at the 58th Annual Meeting of the American Society of Clinical Oncology